Prima in high-level licensing talks
18 February, 2002 by Tanya HollisPrima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Prima BioMed has commenced preliminary talks with several major drug companies over potential licensing options for its new anti-inflammatory compound,VIB 153.
Mettler-Toledo Launches X3 Series to Transform Bulk Flow Inspection with Advanced Detection, Hygienic Design and Precision Rejects
Nestlé’s cocoa diversity research to help safeguard chocolate
Sublime potential of Aussie citrus in food sector applications
Voice technology used to transform cold storage operations
Yume Food enters liquidation, sale process launched